334 related articles for article (PubMed ID: 15141013)
1. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
Mimnaugh EG; Xu W; Vos M; Yuan X; Isaacs JS; Bisht KS; Gius D; Neckers L
Mol Cancer Ther; 2004 May; 3(5):551-66. PubMed ID: 15141013
[TBL] [Abstract][Full Text] [Related]
2. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade.
Mimnaugh EG; Xu W; Vos M; Yuan X; Neckers L
Mol Cancer Res; 2006 Sep; 4(9):667-81. PubMed ID: 16966435
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.
Bonvini P; Dalla Rosa H; Vignes N; Rosolen A
Cancer Res; 2004 May; 64(9):3256-64. PubMed ID: 15126367
[TBL] [Abstract][Full Text] [Related]
4. CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins.
Doong H; Rizzo K; Fang S; Kulpa V; Weissman AM; Kohn EC
J Biol Chem; 2003 Aug; 278(31):28490-500. PubMed ID: 12750378
[TBL] [Abstract][Full Text] [Related]
5. Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.
Peron M; Bonvini P; Rosolen A
BMC Cancer; 2012 Jun; 12():233. PubMed ID: 22691173
[TBL] [Abstract][Full Text] [Related]
6. Antimyeloma activity of heat shock protein-90 inhibition.
Mitsiades CS; Mitsiades NS; McMullan CJ; Poulaki V; Kung AL; Davies FE; Morgan G; Akiyama M; Shringarpure R; Munshi NC; Richardson PG; Hideshima T; Chauhan D; Gu X; Bailey C; Joseph M; Libermann TA; Rosen NS; Anderson KC
Blood; 2006 Feb; 107(3):1092-100. PubMed ID: 16234364
[TBL] [Abstract][Full Text] [Related]
7. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
Neznanov N; Komarov AP; Neznanova L; Stanhope-Baker P; Gudkov AV
Oncotarget; 2011 Mar; 2(3):209-21. PubMed ID: 21444945
[TBL] [Abstract][Full Text] [Related]
8. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway.
Shay KP; Wang Z; Xing PX; McKenzie IF; Magnuson NS
Mol Cancer Res; 2005 Mar; 3(3):170-81. PubMed ID: 15798097
[TBL] [Abstract][Full Text] [Related]
9. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
Blood; 2007 Jun; 109(11):4839-45. PubMed ID: 17299090
[TBL] [Abstract][Full Text] [Related]
11. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Li C; Johnson DE
Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
[TBL] [Abstract][Full Text] [Related]
12. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
Sanderson S; Valenti M; Gowan S; Patterson L; Ahmad Z; Workman P; Eccles SA
Mol Cancer Ther; 2006 Mar; 5(3):522-32. PubMed ID: 16546966
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Zismanov V; Drucker L; Gottfried M
Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
[TBL] [Abstract][Full Text] [Related]
14. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
[TBL] [Abstract][Full Text] [Related]
15. A cell-based screen for inhibitors of protein folding and degradation.
Boschelli F; Golas JM; Petersen R; Lau V; Chen L; Tkach D; Zhao Q; Fruhling DS; Liu H; Nam C; Arndt KT
Cell Stress Chaperones; 2010 Nov; 15(6):913-27. PubMed ID: 20717760
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
17. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.
An WG; Schulte TW; Neckers LM
Cell Growth Differ; 2000 Jul; 11(7):355-60. PubMed ID: 10939589
[TBL] [Abstract][Full Text] [Related]
18. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
19. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.
Marx C; Held JM; Gibson BW; Benz CC
Cancer Res; 2010 May; 70(9):3709-17. PubMed ID: 20406983
[TBL] [Abstract][Full Text] [Related]
20. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
